Clinical Trials Directory

Trials / Completed

CompletedNCT04640285

Nicotine Uptake, Measures of Abuse Liability, and Puffing Topography With Use of RELX ENDS Products by Smokers

A Randomized, Open-Label, Single-Center, Cross-Over Study of Adult Smokers to Assess Nicotine Uptake, Measures of Abuse Liability, and Puffing Topography With RELX Infinity Electronic Nicotine Delivery Systems (ENDS)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
41 (actual)
Sponsor
Cheerain HK Limited · Industry
Sex
All
Age
22 Years – 59 Years
Healthy volunteers
Accepted

Summary

This study is being conducted to evaluate nicotine uptake and exposure, the abuse liability, and puffing topography associated with the use of an electronic nicotine delivery system ENDS with tobacco- and menthol-flavored e-liquids in current smokers.

Conditions

Interventions

TypeNameDescription
OTHERRELX ENDS Tobacco FlavorAd libitum use of RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
OTHERRELX ENDS Menthol FlavorAd libitum use of RELX ENDS Menthol flavor product during 8-hour and 5-minute use sessions
OTHERUsual Brand CigaretteAd libitum use of subjects usual brand product during 8-hour and single cigarette use sessions
OTHERNicorette White Ice Mint nicotine polacrilex gumAd libitum use of Nicorette White Ice Mint nicotine polacrilex gum product during 8-hour and 30-minute use sessions

Timeline

Start date
2020-11-03
Primary completion
2021-03-12
Completion
2021-03-19
First posted
2020-11-23
Last updated
2021-03-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04640285. Inclusion in this directory is not an endorsement.